Clinical Trials

An Open-Label Phase 1/2 Study of JCARH125, BCMA targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma

Study ID
JUNO H125001

NCT Number
NCT03430011 (Click on the NCT number for more information about the trial)

Research Study Number

Principle Investigator
Dr. David Siegel


Juno Therapeutics

Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at

Apply Now